Giordano et al. tested onvansertib and another PLK1 inhibitor (GSK461364) in combination with taxanes (paclitaxel and docetaxel) in a set of triple negative breast cancer cell lines in vitro and in vivo. This evidence concerns the gene PLK1 and triple-negative breast carcinoma.